Prospective study of the effect of rituximab on kidney function in membranous nephropathy.

ABSTRACT:

Background

Patients with membranous nephropathy (MN) and poor kidney function or active disease despite previous immunosuppression are underrepresented in clinical trials. It is unknown how effective rituximab is in this population.

Methods

This prospective, multi-centre, single-arm, real-world study of patients with active MN [urine protein-creatinine ratio (uPCR) >350 mg/mmol and serum albumin <30 g/L, or a fall in estimated glomerular filtration rate (eGFR) of at least 20% or more over at least 3 months] evaluated rituximab in those with contraindications to calcineurin inhibitors and cytotoxic therapy. The primary outcome was change in rate of eGFR decline before and after rituximab. Complete or partial remission were defined as uPCR <30 mg/mmol or uPCR <350 mg/mmol with

SUBMITTER: Kanigicherla DAK 

PROVIDER: S-EPMC11299108 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature